Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

The p53 breast cancer tissue biomarker in Indian women

Authors Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R

Published 11 August 2011 Volume 2011:3 Pages 71—78

DOI http://dx.doi.org/10.2147/BCTT.S20695

Review by Single-blind

Peer reviewer comments 5

This paper has been retracted.
 
Vinayak W Patil1, Mukund B Tayade2, Sangeeta A Pingale1, Shubhangi M Dalvi1, Rajesh B Rajekar1, Hemkant M Deshmukh1, Shital D Patil1, Rajeev Singhai1
1Department of Biochemistry, 2Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India

Background: Combination chemotherapy is highly effective in locally advanced breast cancer. A negative expression of biomarker p53 indicates a higher chance of responding to this regimen. Patients' p53 status may be used as a biological cancer marker to identify those who would benefit from more aggressive treatments.
Aims: The role of p53 in modulating apoptosis has suggested that it may affect the efficacy of anticancer agents. p53 alterations in 80 patients with locally advanced breast cancer IIIB undergoing neoadjuvant chemotherapy were prospectively evaluated.
Materials and methods: Patients received three cycles of paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression, using immunohistochemistry and DNA sequencing.
Results: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of 25 patients who obtained a complete clinical response, only two were classified as p53-positive (P = 0.004, χ2). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, χ2).
Conclusion: Immunohistochemical (IHC) analysis has been shown to be a prognostic factor for patients with breast cancer in India. Paclitaxel is one of the most promising anticancer agents for the therapy of breast cancer, where it has also shown activity in tumors resistant to doxorubicin.

Keywords: breast cancer, doxorubicin, p53, paclitaxel, cancer tissue biomarkers, neoadjuvant chemotherapy, immunohistochemistry, infiltrating duct cancer


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Other articles by this author:

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women

Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW

Breast Cancer: Targets and Therapy 2011, 3:27-33

Published Date: 19 April 2011

Cancer biomarker HER-2/neu in breast cancer in Indian women

Singhai R, Patil VW, Patil AV

Breast Cancer: Targets and Therapy 2011, 3:21-26

Published Date: 29 March 2011

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al

Breast Cancer: Targets and Therapy 2011, 3:9-19

Published Date: 16 March 2011

Readers of this article also read:

Ceftobiprole for the treatment of pneumonia: a European perspective

Liapikou A, Cillóniz C, Torres A

Drug Design, Development and Therapy 2015, 9:4565-4572

Published Date: 18 August 2015

Randomized controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis

Cantoresi F, Caserini M, Bidoli A, Maggio F, Marino R, Carnevale C, Sorgi P, Palmieri R

Clinical, Cosmetic and Investigational Dermatology 2014, 7:185-190

Published Date: 27 May 2014

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C

Clinical Pharmacology: Advances and Applications 2014, 6:61-62

Published Date: 27 March 2014

Photodynamic therapy of a 2-methoxyestradiol tumor-targeting drug delivery system mediated by Asn-Gly-Arg in breast cancer

Shi J, Wang Z, Wang L, Wang H, Li L, Yu X, Zhang J, Ma R, Zhang Z

International Journal of Nanomedicine 2013, 8:1551-1562

Published Date: 19 April 2013

Controlled-release approaches towards the chemotherapy of tuberculosis

Saifullah B, Hussein MZ, Hussein Al Ali SH

International Journal of Nanomedicine 2012, 7:5451-5463

Published Date: 12 October 2012

True story about HIV: theory of viral sequestration and reserve infection

Barasa S

HIV/AIDS - Research and Palliative Care 2011, 3:125-133

Published Date: 8 December 2011

Current and developing therapeutic agents in the treatment of Chagas disease

Werner Apt

Drug Design, Development and Therapy 2010, 4:243-253

Published Date: 17 September 2010

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010